While the sector at large has performed well of late, certain companies such as Actavis plc (ACT +0.00%) have still beaten the broader market by leaps and bounds, as the following chart shows. Actavis ...

Tris Pharma accused proposed Actavis generic of infringing patents Federal Circuit upheld patents after second time hearing case (Reuters) - A U.S. appeals court on Thursday upheld three Tris Pharma ...

-First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea - IBS-D can be debilitating, affecting up to 15 million Americans, and there are limited therapeutic.

(Reuters) - Generic drugmaker Actavis Plc (ACT.N) said on Tuesday it would buy Forest Laboratories Inc (NYS:FRX) for about $25 billion (14 billion pounds) in cash and stock, expanding its portfolio of ...

Global pharmaceutical company Actavis, which focuses on producing generic versions of name-brand prescriptions, announced Tuesday morning that it is buying the America-based Forest Labs in a deal ...

Investors in drugmaker Actavis may be waking up to risks they initially didn't recognize. The stock was down more than 1 percent Wednesday as analysts warned an antitrust lawsuit filed by New York ...

Actavis today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) to commercialize MoxDuo® IR in the ...